the hepatitis b virus is a major public health problem worldwide and is a major public health problem worldwide. the development of new therapies for coronaviruses is rapidly evolving and is now being challenged by the development of new therapies for coronaviruses. we are now working on a new strategy to address this global health crisis and we are now working with the covid-19 research effort. we will continue to move forward with our clinical development program for a new new capsid inhibitor, b-836 and a new new oral b. hepatitis b specific RNA destabilizer and a lead oral compound that inhibits p-l1. we will also continue our research efforts for a next- generation oral b. hepatitis b specific RNA destabilizer and a lead oral compound that inhibits p-l1.